Chemotherapy for Testicular Cancer
|
|
- Nickolas Cole
- 7 years ago
- Views:
Transcription
1 Chemotherapy for Testicular Cancer Jeremy Cetnar, MD Assistant Professor of Medicine Genitourinary Oncology and Experimental Therapeutics Program University of Wisconsin Comprehensive Cancer Center University of Wisconsin Carbone Cancer Center
2 Outline Epidemiology Staging Treatments Chemotherapy Stage I Adjuvant Recurrent disease
3 Epidemiology 90% of germ cell tumors (GCTs) arise in testis GCTs are the most common solid tumors in men age15-35 In 2009, 8400 new cases, 380 deaths ACS, cancer facts 2009 Highest incidence in Germany, Scandinavia, and Switzerland Lowest incidence in Africa and Asia Risk Factors Race: caucasians >>>blacks Age: bimodal: 20-30s and >50s Cryptorchidism 4-40x higher compared to normal Risk persists despite orchiopexy Kleinfelter syndrome Family History: up to 6x greater risk, greatest for siblings Infertility Contralateral GCT
4 Histology NSCGT Seminoma
5 Seminoma Most frequently present in those 35 to 45 years old On IHC, + PLAP, C-kit (CD117), VASA, NANOG, and OCT4 Rarely produces HCG (from syncytiotrophoblasts) Does not influence prognosis NEVER PRODUCE AFP* Nazeer T, Oncol Rep, 1998; 2 cases of pure seminoma producing AFP Have a greater propensity to met to bone compared to NSGCT 80% present with stage 1 disease
6 Nonseminomatous GCTs Typically present in the 20s Four most common types Embryonal carcinoma Choriocarcinoma Yolk Sac tumor Teratoma Most tumors are mixed with a combination of types including seminoma Note: Any element of a non-seminoma makes the tumor a NSGCT
7 NSGCT Embryonal: Most common component of mixed NSGCT AFP and HCG are commonly elevated Poorly defined histologically Areas of necrosis and hemorrhage frequently seen Choriocarcinoma: Consists of both syncytiotrophoblast and cytotrophoblasts Results in very high HCG levels (>100K) Spreads hematogenously Results in bleeding Mets to brain and lung commonly
8 NSGCT Teratoma Derived from ectoderm, endoderm, and mesoderm Able to differentiate Mature teratoma contains adult type differentiated tissue Immature teratoma contain partial somatic differentiation Teratoma with malignant transformation resembles a non-gct somatic cancer (ie; sarcoma, carcinoma, leukemia) Yolk Sac Tumor Demonstrates extraembryonic yolk sac differentiation Most common germ cell tumor in children Makes AFP Most common mediastinal NSGCT Ten different histologic subtypes
9 Pathogenesis 100% of GCTs show an increased copy of 12p Genes associated with 12p CCND2 oncogene GLUT3 glucose transporter GAPDH and TP11 glycolytic enzymes NANOG, DPPA3, and GDF3 self renewal and pluripotency Carcinoma in situ (ITGCN) is the precursor for GCTs Median time of 5 years until progression invasive ca.
10 Anatomy Initial route of metastasis is lymphatic drainage to the retroperitoneal lymph nodes Right testicular tumor drains into interaortocaval inferior to the renal vessels Right testicular a/v from aorta and IVC Left testicular tumor drains into the para-aortic nodes inferior to the left renal vessels Left testicular a/v from left renal artery and left vein
11 Staging CT of the chest, abdomen, and pelvis Tumor markers AFP: ½ life of 5-7 days HCG: ½ life of 30 hours LDH
12 Clinical staging General rules Stage 1: Tumor confined to the testis Stage 2: Tumor confined to the testis and retroperitoneum Stage 3: Metastatic
13 TNM Staging
14 Germ Cell Tumor Risk Classification
15 Advanced GCTs IGCCCG risk % of population 5-year survival (%) Good Intermediate Poor J Clin Onc, 1997
16 Stage 1 Seminoma Radiation Stage 1 Seminoma Observation Chemotherapy
17 Treatment: Stage 1 Seminoma Risk factors for relapse >4cm and rete testis invasion 0 = 8%, 1 = 10-15%, 2 = 25% Median time to relapse: months 30% of relapses occur after 2 years 5% of relapses occur after 5 year 1. Radiation 2500 cgy Relapse rate of 3-5% after radiation Typically in the posterior mediastinum or suplaclavicular area 2. Observation
18 Treatment: Stage 1 Seminoma cont. 1. Radiation 2. Observation 3. Chemotherapy: Single dose of carboplatin 1477 patients randomized to XRT or carboplatin After four years relapse rate of 95% for chemo vs. 96% for XRT Two cycles of carboplatin 3.3% relapse Criticisms Still need regular imaging of the retroperitoneum Carboplatin inferior to cisplatin Long term consequences of 1-2 cycles of carbo unknown
19 Stage 1 NSGCT RPLND Stage 1 NS Observation Chemotherapy
20 Treatment: Stage 1 NSGCT 1. RPLND Both diagnostic AND therapeutic Most consistent long term morbidity is retrograde ejaculation If lymph nodes are positive then what? If pn % chance of recurrence If pn2-3 50% chance of micrometastatic disease 2 cycles of Etoposide/Cisplatin
21 RPLND Modified bilateral retroperitoneal lymph node dissection Devita, 2008
22 Treatment: Stage 1 NSGCT 1. RPLND 2. Observation Why? Retrograde ejaculation after RPLND Most would not have needed RPLND Ability of cisplatin chemotherapy to cure systemic disease >50% chance of recurrence if > pt2 (+/- embryonal) If pt1 = 15% chance of recurrence <10% of relapses occur more than 2 years after diagnosis (compared with 30% in seminoma) Sites of relapse: retroperitoneum (2/3) markers or lungs (1/3)
23 Treatment: Stage 1 NSGCT 1. RPLND 2. Observation 3. Chemotherapy 2 cycles of BEP 5% relapsed and 1% death rate 1 cycle of CVB for LVI patients No difference in relapse rate compared to observation 2 cycles of CVB for LVI+ patients Reduced recurrence rate by >90% ¼ of patients had grade ¾ obstipation or infection
24 Treatment 1: Stage 1 NSCGT What should you do if the markers do not normalize or plateau after orchiectomy?
25 Treatment: Stage 2 GCTs Remember the clinical staging: 2A: <2cm 2B: >2cm but less than 5cm 2C: >5cm Seminoma 2A and 2B XRT NSGCT Same dosage of radiation for stage 1 but in a dog leg distribution Relapse <10% 2A RPLND If pn1: 15-20% chance of relapse observation If pn2-3: 50% of micrometastatic disease 2 of EP
26 Treatment: Stage 2 GCTs For NSGCT stage 2B and 2C and seminoma 2C Treat as advanced disease (chemotherapy) Idenitification for relapse: Stage 1 NSGCT: Observation: PE, tumor markers, and CXR monthly, and CT every 3 months during year #1 PE, tumor markers, CXR every other month and CT every four months during year #2 PE, tumor markers, and CXR every three months and CT every 6 months for years 3-5 Beyond 5 years yearly markers, CXR, and PE If undergoing XRT no need for abdominal CT If undergoing RPLND no need for abdominal CT
27 Treatment of advanced disease Unresectable stage 2 NSGCT/Seminoma Includes extensive or bulky retroperitoneal, supradiaphragmatic nodal or visceral mets Advanced disease Good risk: 3 cycles of BEP Bleomycin 30 units (D 1,8,15) Cisplatin 20mg (D1-5) Etoposide 100mg/m2 (D1-5) 21 day cycle Need G-CSF If wanting to avoid bleomycin: 4 cycles of EP Etoposide 100mg (D1-5) Cisplatin 20mg (D1-5)
28 Treatment: Int/Poor risk GCTs 4 cycles of BEP is the standard If wanting to avoid bleomycin toxicity may use 4 VIP Equivalent efficacy but increased hematologic toxicity Etoposide 75mg (D1-5) Ifosphamide 1.2grams (D1-5) Cisplatin 20mg (D1-5)
29 High dose chemotherapy Does high dose chemotherapy for intermediate/poor as initial treatment improve survival? JCO, 2007, Motzer R 219 patients with I/P risk GCT randomized to either 4 cycles of BEP 2 cycles of BEP followed by high dose carbo, etoposide, cytoxan
30 Post chemotherapy treatment If a residual mass remains following chemotherapy for NSGCT RESECT!!! PET scan not reliable Biggest concern is viable carcinoma or teratoma Teratoma is relatively chemotherapy insensitive and may grow or transform therefore it must be resected In the retroperitoneum: necrosis 45-50%, teratoma 35-40%, viable 10-15% Predictors of viable mass: presence of teratoma in the original tumor, pre-op tumor markers, and size of mass post-chemo If viable tumor is present then 2 cycles of EP are indicated If necrosis or teratoma no further therapy indicated If residual mass in lung or mediastinum resect, more likely to be residual tumor or teratoma
31 Post-chemotherapy seminoma Unlike NSGCT, PET scan is helpful in identifying if viable tumor is present in a residual mass If residual mass is <3cm then observe If residual mass is >3cm then PET If positive then higher risk for viable tumor Unlike NSGCT, teratoma is unlikely in the residual mass Unlike NSGCT, RPLND following chemotherapy is more difficult due to desmoplastic reaction and obliteration of tissue planes
32 Relapsed disease 20-30% will relapse following initial chemotx. Most relapses occur within 2 years Standard salvage regimens include VeIP x 4 (Vinblastine, ifosfamide, and cisplatin) OR TIP x 4 (paclitaxel, ifosfamide, and cisplatin) Devita, 2008
33 Relapsed disease Defining relapse Primary refractory: progression either during or within four weeks of finishing initial chemotherapy Poor prognosis with <10% 3yr survival with conventional dose salvage regimens Treatment is typically high dose chemotherapy with stem cell rescue If relapsing mediastinal NSGCT then also a poor prognosis and should consider HD chemotherapy Late relapse: > 2 years from initial chemotherapy Typically slow growing and chemo resistant For NSGCT surgical resection +/- chemo is critical For seminoma, tend to behave like early relapsing Treat with chemotherapy since teratomas are rare
34 HD chemo for refractory disease GCTs are chemosensitive, could more chemo be better? As first line treatment in poor risk GCTs compared to standard BEP Motzer R, JCO, patients with either Intermediate or poor risk Randomized to either 4 BEP or 2 BEP followed by 2 HDSCR HD= carbo, etop, and cytoxan No difference in OS
35 High dose chemotherapy As first line therapy for salvage treatment Pico JL, Annals of Oncology, patients with complete or partial response to first line cisplatin based chemotherapy Randomized to either VeIP or EIP x 4 or VeIP or EIP x 3 then carbo, etoposide and cytoxan x 1 No difference in 3yr survival 7% death rate with HD chemo compared to 3% with standard
36 High dose chemotherapy What is the role of high dose chemo with stem cell rescue? Primary refractory Relapse after standard VeIP or TIP Relapsing mediastinal NSGCT? The University of Indiana Experience Retrospective study 184 patients who received HD chemotherapy Testicular tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell rescue, even when this regimen is used as third-line or later therapy or in patients with platinum-refractory disease Einhorn, NEJM, 2007
37 Einhorn LH et al. N Engl J Med 2007;357:
38
39 Boards Growing teratoma syndrome
40
41
42
Testicular Cancer. Page 1 of 17 TABLE OF CONTENTS
Testicular Cancer te: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 17 TABLE OF CONTENTS Suspicious Testicular Cancer Page 2 nseminomatous Germ Cell Tumor (NSGCT): workup
Small Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
J Clin Oncol 23:6149-6156. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 25 SEPTEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Guidelines on Testicular Cancer
Guidelines on Testicular Cancer P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg European Association of Urology
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
Kidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
This testicular cancer management guide covers the diagnosis, staging, and treatment of germ-cell tumors and seminoma.
November 01, 2015 Cancer Management [1] By Nasser H. Hanna, MD [2], Costantine Albany, MD [3], Patrick J. Loehrer, Sr, MD [4], Atreya Dash, MD [5], Jenny Shaffer, MD [6], Mark K. Buyyounouski, MD, MS [7],
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 06/22/2012
A912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
Testicular Cancer. What is cancer?
What is cancer? Testicular Cancer The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly way. During the early years of a person s life,
LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
Testicular Cancer. What is cancer?
What is cancer? Testicular Cancer The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly way. During the early years of a person s life,
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Small Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
Diagnosis and Prognosis of Pancreatic Cancer
Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.
Testicular Cancer Overview
Testicular Cancer Overview This overview is based on the more detailed information in Testicular Cancer. You can get this document and other information by calling 1-800-227-2345 or you can read it on
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
Mesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
Pediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
Cycle frequency: Every three weeks Total number of cycles: 3 or 4
BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs
95% of childhood kidney cancer cases are Wilms tumours. Childhood kidney cancer is extremely rare, with only 90 cases a year in
James Whale Fund for Kidney Cancer Childhood kidney cancer factsheet Kidney cancer rarely afflicts children and about 90 paediatric cases are diagnosed in the UK each year. About 75% of childhood kidney
Management of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
Update on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
How To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
Ovarian tumors Ancillary methods
Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Stage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors Lawrence H. Einhorn, M.D., Stephen D. Williams, M.D.,
بسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
Malignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
THYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Understanding Metastatic Disease
Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
People Living with Cancer
Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
Surgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
Thyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
Hepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
Lung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT
te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm
Post-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
Case Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
Radiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
Frequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
LIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
Subject: Hematopoietic Stem Cell Transplantation for Germ Cell Tumors 9/17/14
Subject: Hematopoietic Stem Cell Transplantation for Germ Cell Tumors Original Effective Date: 9/17/14 Guidance Number: MCG-194 Revision Date(s): SUMMARY Germ cell tumors Germ cell tumors are a type of
Overview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology. Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Table of Contents Data Supplement 1: Summary of included
Martijn Kerst. Stadium I testis carcinoom. Gevorderd stadium.
Martijn Kerst Stadium I testis carcinoom en dan Gevorderd stadium. En dan Dutch registry 24% of all tumors in male 15-44 yr Rising incidence 1989 336 2011 725 55% seminoma 45 % non-seminoma 2/3 presenting
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
Frequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
Histopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
TESTICULAR CANCER LUMPS AND SELF-EXAMINATION A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM
TESTICULAR CANCER LUMPS AND SELF-EXAMINATION A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM First published in October 2003 by Andrology Australia 4th Edition May 2014 Copyright
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
Radiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.
Directly Coded Summary Stage Is Back
Directly Coded Summary Stage Is Back Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry June 30, 2015 1 Outline What is SEER Summary Stage 2000 (SS2000)? Summary Stage Housekeeping
Introduction. Case History
NAOSITE: Nagasaki University's Ac Title Author(s) A Case Report of Renal Cell Carcino Shimajiri, Shouhei; Shingaki, Yoshi Masaya; Tamamoto, Tooru; Toda, Taka Citation Acta Medica Nagasakiensia. 1992, 37
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
Breast Cancer Follow-Up
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Follow-Up Breast Cancer Follow-Up Version 2002: Thomssen / Scharl Version 2003 2009: Bauerfeind / Bischoff /
Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
Primary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
Guidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY CASE HISTORY 52Y MALE RIGHT RADICAL NEPHERECTOMY Case of right renal mass with IVC thrombus. History of surgery and RT for right occipital
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos